PHASE II Comprehensive ICOHRTA AIDS/TB (U2R)

The summary for the PHASE II Comprehensive ICOHRTA AIDS/TB (U2R) grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.

PHASE II Comprehensive ICOHRTA AIDS/TB (U2R): -Purpose. This Funding Opportunity Announcement (FOA), PAR-08-155, issued by FIC, NIMH, ORWH, and NIDA, NIH solicits renewal (re-competing) and new Phase II applications in the International Clinical, Operations and Health Services Research Training Award for AIDS and TB (ICOHRTA AIDS TB) program. The applications from a Research Training Unit , composed of a Phase I ICOHRTA AIDS TB (planning grant) recipient and the U.S. partner institution chosen by the Phase I recipient, must propose, in an integrated manner, a comprehensive training program that will strengthen the capacity in the foreign country to conduct clinical research and implementation science, including operations and health services research focused on HIV infection, TB, and, where relevant, HIV/TB co-infection prevention, care and treatment. -Mechanism of Support. This FOA will utilize the International Training Cooperative Agreement (U2R) grant mechanism -Funds Available and Anticipated Number of Awards The estimated amount of funds available for support of five-six new or renewal Research Training Units awarded as a result of this announcement is $3,000,000 for fiscal year 2009. Future year amounts will depend on annual appropriations. Facilities and administrative costs are limited to 8% for all awards and sub-awards. The earliest anticipated start dates for awards are April 1, 2009.

Federal Grant Title:	PHASE II Comprehensive ICOHRTA AIDS/TB (U2R)
Federal Agency Name:	National Institutes of Health
Grant Categories:	Education Health Income Security and Social Services
Type of Opportunity:	Discretionary
Funding Opportunity Number:	PAR-08-155
Type of Funding:	Cooperative Agreement
CFDA Numbers:	93.279
CFDA Descriptions:	Drug Abuse and Addiction Research Programs
Current Application Deadline:	Aug 18, 2009
Original Application Deadline:	Aug 18, 2009
Posted Date:	Dec 02, 2008
Creation Date:	Dec 02, 2008
Archive Date:	Sep 18, 2009
Total Program Funding:	$3,000,000
Maximum Federal Grant Award:	$275,000
Minimum Federal Grant Award:
Expected Number of Awards:
Cost Sharing or Matching:	No

Applicants Eligible for this Grant: Public and State controlled institutions of higher education - Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education - Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education - Private institutions of higher education - Others (see text field entitled "Additional Information on Eligibility" for clarification)
Additional Information on Eligibility: Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Non-domestic (non-U.S.) Entities (Foreign Organizations); Tribally Controlled Colleges and Universities (TCCUs) ; New applications for a Phase II Comprehensive ICOHRTA-AIDS/TB Award will only be accepted from foreign institutions that were awarded a planning grant under Phase I ICOHRTA AIDS TB program announcement and the U.S. non-profit partner institution that the planning grant recipient has chosen. The foreign and U.S. partner applicant institutions must have achieved a strong record of receiving or being significantly involved in HIV/AIDS and/or TB international research. Both the foreign and U.S. partner institutions must demonstrate the capacity and leadership necessary for the successful implementation and long-term productivity of the program. Renewal applications will only be accepted from existing ICOHRTA AIDS TB recipients. Any changes in applicant institutions for U.S. partners need to be well justified.
Link to Full Grant Announcement: Information not provided
Grant Announcement Contact: NIH OER [email protected]
If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster [[email protected]]
Similar Government Grants: • Using Neuromodulation to Characterize the Continuum of Pathophysiology Between Substance U...; • Education Activities for Responsible Analyses of Complex, Large-Scale Data (R25- Clinical ...; • Research on the Neuro-Immune Axis in the context of HIV and Substance Use (R01 Clinical Tr...; • Research on the Neuro-Immune Axis in the Context of HIV and Substance Use (R21 Clinical Tr...; • Developing Digital Therapeutics for Substance Use Disorders (UG3/UH3 Clinical Trial option...; • NIDA Phase II Small Business Innovation Research (SBIR [R44]) Competing Renewal Awards; • Drug Abuse Aspects of Hiv/Aids and Other Infections; • Epidemiology of Drug Abuse
More Grants from the National Institutes of Health: • SBIR Phase IIB Bridge Awards to Accelerate the Development of Cancer-Relevant Technologies...; • Small Business Transition Grant For Early Career Scientists (R41/R42 Clinical Trial Not Al...; • Cystic Fibrosis Research and Translation Centers (P30 Clinical Trial Optional); • Mentored Quantitative Research Development Award (Parent K25 Independent Clinical Trial No...; • Mentored Quantitative Research Development Award (Parent K25 Independent Basic Experimenta...